George Fennell Sells 9,986 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) EVP George Fennell sold 9,986 shares of the company's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

IDEXX Laboratories Stock Down 3.3 %

Shares of IDXX stock traded down $15.23 during trading hours on Friday, reaching $444.53. The company had a trading volume of 553,751 shares, compared to its average volume of 753,210. The company has a market capitalization of $36.40 billion, a P/E ratio of 41.66, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The stock's fifty day simple moving average is $430.95 and its 200 day simple moving average is $453.11. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31.

Analyst Ratings Changes

A number of research firms recently issued reports on IDXX. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Wednesday, February 5th. Morgan Stanley dropped their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price objective for the company. Finally, Piper Sandler raised their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

Institutional Trading of IDEXX Laboratories

A number of hedge funds have recently made changes to their positions in IDXX. Chicago Partners Investment Group LLC lifted its holdings in IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock worth $340,000 after buying an additional 96 shares in the last quarter. National Pension Service boosted its holdings in IDEXX Laboratories by 7.3% in the third quarter. National Pension Service now owns 185,972 shares of the company's stock valued at $93,957,000 after purchasing an additional 12,647 shares during the last quarter. Insight Wealth Strategies LLC boosted its holdings in IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after purchasing an additional 7,041 shares during the last quarter. Larson Financial Group LLC boosted its holdings in IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after purchasing an additional 2,241 shares during the last quarter. Finally, Quest Partners LLC boosted its holdings in IDEXX Laboratories by 4,059.4% in the third quarter. Quest Partners LLC now owns 2,870 shares of the company's stock valued at $1,450,000 after purchasing an additional 2,801 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.